Phase II trial of tanespimycin (KOS-953), a heat shock protein-90 (Hsp90) inhibitor in patients with metastatic melanoma

被引：0
|
作者：
Kefford, R.
Millward, M.
Hersey, P.
Brady, B.
Graham, M.
Johnson, R. G.
Hannah, A. L.
机构：
[1] Westmead Hosp, Wentworthville, Australia
[2] Sir Charles Gairdner Hosp, Nedlands, WA, Australia
[3] Univ WA, Nedlands, WA, Australia
[4] Univ Newcastle, Newcastle, NSW, Australia
[5] Cabrini Hlth Private Hosp, Malvern, Australia
[6] Kosan Biosci, Hayward, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8558
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Phase II Trial of AUY922, a Heat Shock Protein 90 (HSP90) Inhibitor, in ALK-Positive Lung Cancer Patients Previously Treated with ALK Inhibitors
    Gainor, Justin F.
    Marcoux, J. P.
    Rabin, Michael
    Gandhi, Leena
    Costa, Daniel B.
    Logan, Jennifer
    Jackman, David M.
    Shaw, Alice
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S649 - S649
  • [32] Clinical and Biologic Activity of the Heat Shock Protein-90 (HSP-90) Inhibitor 17-AAG in Patients with Relapsed Lymphoma
    Younes, Anas
    Copeland, Amanda R.
    Romaguera, Jorge
    Fayad, Luis
    Fanale, Michelle
    Faria, Silvana de Castro
    Medeiros, L. Jeffrey
    Ivy, S. Percy
    BLOOD, 2009, 114 (22) : 1441 - 1441
  • [33] HEAT-SHOCK PROTEIN-90 (HSP90) MESSENGER-RNA LEVELS FOLLOWING TRANSIENT ISCHEMIA OF GERBIL BRAIN
    WIESSNER, C
    MIES, G
    DUX, E
    HOSSMANN, KA
    EUROPEAN JOURNAL OF NEUROSCIENCE, 1992, : 240 - 240
  • [34] Overcoming resistance to tyrosine kinase inhibitors (TKIs) through inhibition of Heat Shock Protein 90 (Hsp90) chaperone function in patients with metastatic GIST: results of a Phase I Trial of IPI-504, a water-soluble Hsp90 inhibitor
    Demetri, G. D.
    George, S.
    Morgan, J. A.
    van den Abbeele, A.
    Quigley, M. T.
    Fletcher, J. A.
    Normandt, E.
    Patterson, J.
    Adams, J.
    Grayzel, D.
    EJC SUPPLEMENTS, 2006, 4 (12): : 173 - 173
  • [35] Reactive cysteines of the 90-kDa heat shock protein, Hsp90
    Nardai, G
    Sass, B
    Eber, J
    Orosz, G
    Csermely, P
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 384 (01) : 59 - 67
  • [36] A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer
    Lipika Goyal
    Surendra Pal Chaudhary
    Eunice L. Kwak
    Thomas A. Abrams
    Amanda N. Carpenter
    Brian M. Wolpin
    Raymond C. Wadlow
    Jill N. Allen
    Rebecca Heist
    Nadine Jackson McCleary
    Jennifer A. Chan
    Wolfram Goessling
    Deborah Schrag
    Kimmie Ng
    Peter C. Enzinger
    David P. Ryan
    Jeffrey W. Clark
    Investigational New Drugs, 2020, 38 : 1533 - 1539
  • [37] Potential role of heat shock protein 90 (Hsp90) in HIV uncoating
    Pheroze Joshi
    Cheryl A Stoddart
    Retrovirology, 8 (Suppl 2)
  • [38] A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer
    Goyal, Lipika
    Chaudhary, Surendra Pal
    Kwak, Eunice L.
    Abrams, Thomas A.
    Carpenter, Amanda N.
    Wolpin, Brian M.
    Wadlow, Raymond C.
    Allen, Jill N.
    Heist, Rebecca
    McCleary, Nadine Jackson
    Chan, Jennifer A.
    Goessling, Wolfram
    Schrag, Deborah
    Ng, Kimmie
    Enzinger, Peter C.
    Ryan, David P.
    Clark, Jeffrey W.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1533 - 1539
  • [39] Progress in the Discovery and Development of Heat Shock Protein 90 (Hsp90) Inhibitors
    Bhat, Rohit
    Tummalapalli, Sreedhar R.
    Rotella, David P.
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (21) : 8718 - 8728
  • [40] Clinical and biological significances of heat shock protein 90 (Hsp90) in human nasopharyngeal carcinoma cells and anti-cancer effects of Hsp90 inhibitor
    Liu, Fangxian
    Wang, Liangliang
    Yi, Shijiang
    Liu, Qianghe
    Xu, Xiaoxiao
    Su, Min
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 120
12345